ONI(ONIT)

Focus: ONI is a publicly traded biotechnology company specializing in super-resolution microscopy technology, operating as an enabling platform for drug discovery and development. Founded in 2016 and headquartered in West Palm Beach, FL, the company generated $1.1B in revenue in FY 2025.

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About ONI

AI assessmentNot Hiring

No open roles listed right now. Follow ONI to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$1.1B

Recent News · ONI(2)

SafetyFDA

Mar 11, 2026

FDA Launches New Adverse Event Look-Up Tool

FDA launched a new unified platform for analyzing adverse event reports. This platform — called the FDA Adverse Event Monitoring System (AEMS) — represents a major achievement in the agency’s mission to modernize and provide radical transparency into the safety of regulated products.

Help build intelligence for ONI

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status with $202M cash position provides institutional stability and access to public equity upside
Specialized focus on super-resolution microscopy represents a differentiated enabling technology platform with broad R&D applications
Strong revenue growth (+15% YoY from $954M in FY2024 to $1.1B in FY2025) demonstrates market validation and business momentum

Watch Out For

No active clinical pipeline (zero Phase 1, Phase 2, Phase 3 programs) indicates limited near-term clinical catalysts and therapeutic upside
FY 2025 net loss of $63.7M represents significant profitability decline from $26M profit in FY 2024, signaling operational stress despite revenue growth

Generated by Claude from ONI's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2016

Publications: 29 in PubMed

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$1.1B12%

Net Income

-$64M

Cash

$202M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Operando ATR-FTIR elucidation of surface-mediated photocatalytic pathways on metal-free nanomaterials.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

2026

PMID:41864001

The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity.

Hypertension research : official journal of the Japanese Society of Hypertension

Showing 5 of 10 publications